819813-71-3

Basic information

• Product Name: Benzoic acid, 3,4-bis(2-methoxyethoxy)-
• CAS NO: 819813-71-3
• Molecular Formula: C13H18O6
• Molecular Weight: 270.282
• Mol File: 819813-71-3.mol

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 3,4-bis(2-methoxyethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3,4-bis(2-methoxyethoxy)-(819813-71-3)
• EPA Substance Registry System: Benzoic acid, 3,4-bis(2-methoxyethoxy)-(819813-71-3)

Safety Data

• Hazardous Substances Data: 819813-71-3(Hazardous Substances Data)

Upstream product

• 99-50-3 3,4-Dihydroxybenzoic acid 
• 627-42-9 2-chloroethyl methyl ether 
• 179688-14-3 methyl 3,4-bis{[2-(methyloxy)ethyl]oxy}benzoate 
• 2150-43-8 3,4-dihydroxybenzoic acid methyl ester 
• 80407-64-3 3,4-bis(2-methoxyethoxy)benzaldehyde 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 121-33-5 vanillin 
• 183322-16-9 3,4-bis(2-methoxyethoxy)benzoic acid ethyl ester 
• 3943-89-3 Ethyl protocatechuate 

Downstream Products

• 80407-68-7 3,4-bis(2-methoxyethoxy)-benzonitrile 
• 236750-65-5 4,5-bis(2-methoxyethoxy)-2-nitrobenzonitrile 
• 1418289-91-4 3,4-bis(2-methoxyethoxy)-benzamide 
• 950596-58-4 2-amino-4,5-bis-(2-methoxyethoxy)-benzonitrile 
• 950596-59-5 N′-[2-cyano-4,5-{bis(2-methoxyethoxy)phenyl}]-N,N-dimethylformamidine 
• 183321-74-6 erlotinib 
• 183319-69-9 erlotinib hydrochloride 
• 179688-29-0 6,7-bis(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one 
• 501684-22-6 methyl 4,5-bis(2-methoxyethoxy)-2-nitrobenzoate 
• 476168-17-9 2-amino-4,5-bis-(2-methoxyethoxy)-benzoic acid methyl ester 
• 179688-14-3 methyl 3,4-bis{[2-(methyloxy)ethyl]oxy}benzoate 
• 183322-16-9 3,4-bis(2-methoxyethoxy)benzoic acid ethyl ester 
• 179688-26-7 2-nitro-4,5-bis(2-methoxyethoxy)benzoic acid ethyl ester 
• 1447828-82-1 N¹-(6,7-bis(2-methoxyethoxy)quinazolin-4-yl)-N³,N³-bis(2-chloroethyl)benzene-1,3-diamine hydrochloride 

Relevant articles and documents

KINASE INHIBITORS

Compounds that inhibit kinase Lck or Btk, pharmaceutically acceptable salts, hydrides, stereoisomers and pharmaceutical compositions thereof are disclosed.

Bacterial Cell Growth Inhibitors Targeting Undecaprenyl Diphosphate Synthase and Undecaprenyl Diphosphate Phosphatase

We synthesized a series of benzoic acids and phenylphosphonic acids and investigated their effects on the growth of Staphylococcus aureus and Bacillus subtilis. One of the most active compounds, 5-fluoro-2-(3-(octyloxy)benzamido)benzoic acid (7, ED50

Preparation method of erlotinib intermediate

The invention relates to a preparation method of an erlotinib intermediate. The method concretely comprises the following steps: 1, dissolving vanillin in an organic solvent I, adding aluminum trichloride, adding pyridine in a dropwise manner, and reacting to obtain ELTA; 2, dissolving the ELTA in an organic solvent II, adding 2-chloroethylmethyl ether, potassium carbonate and a phase transfer catalyst, and reacting to obtain ELTB; 3, adding the ELTB to water, adding an alkali and potassium permanganate, and reacting to obtain ELTC; 4, adding concentrated sulfuric acid to methanol in a dropwise manner, adding the ELTC to the above reaction system, and reacting to obtain ELTD; 5, adding concentrated sulfuric acid to concentrated nitric acid in a dropwise manner, dissolving the ELTD in an organic solvent IV, adding a prepared mixed acid to the reaction system, and reacting to obtain ELTE; 6, adding the ELTE, iron powder and ammonium chloride to an organic solvent V, adding concentrated hydrochloric acid in a dropwise manner, and reacting to obtain ELTF; and 7, adding the ELTF, trimethyl orthoformate and ammonium acetate to an organic solvent VI, and reacting to obtain the erlotinib intermediate.

A Mild and Regioselective Route to Functionalized Quinazolines

A Rh-catalyzed ortho-amidation cyclocondensation sequence gave a range of 4-aminoquinazolines in high yield. The method features a remarkably mild C(sp2)-H activation step and can be exploited to rapidly access compounds with established biological activity.

An improved convergent approach for synthesis of erlotinib, a tyrosine kinase inhibitor, via a ring closure reaction of phenyl benzamidine intermediate

An improved convergent and economical method has been developed for the synthesis of erlotinib, a 4-anilinoquinazoline and an EGFR-tyrosine kinase inhibitor for treatment of non-small-cell lung cancer. The final two steps for the formation of this 4-anilinoquinazoline from suitable 2-aminobenzonitrile intermediate and 3-ethynylaniline were modified and were performed in a simple one-pot reaction. The ring-closing mechanism for the formation of erlotinib from the suitable formamidine intermediate and 3-ethynylaniline was investigated and determined to proceed via the formation of phenyl benzamidine intermediate rather than involving Dimroth rearrangement reported earlier. The new benzamidine intermediate was isolated for the first time and characterized. Copyright

HSP90 FAMILY PROTEIN INHIBITORS

The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; R1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR7R8 or the like; R2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R3 and R5, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and R4 and R6, which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.